Newsroom

Actions

160531 PR VI ORIENT trial EN

Actions

Compelling Efficacy and Safety Data for Orsiro Hybrid Drug-Eluting Stent Presented during EuroPCR Hotline Session

ORIENT Trial Establishes Orsiro’s Non-Inferiority to Resolute Integrity Stent, while a STEMI Subgroup from the BIOSCIENCE Trial Has 50 Percent Lower TLF Rate vs. Competitor Xience






Please contact us if you require further information

${loading}